Clinical study to investigate whether tofogliflozin increased plasma magnesium level regulates sympathetic tone in type 2 diabetes - COMT study

Shimane University Faculty of Medicine0 个研究点目标入组 30 人开始时间: 2022年6月14日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•Those patients who meet one of the following criteria are excluded: 1. Patients with type 1 diabetes, or secondary diabetes 2. Patients with poor blood glucose control (HbA1c 10% or above) 3. Patients who are taking the medication with magnesium (including Mg supplement) 4. Patients who are taking loop diuretic or thiazide diuretic agents 5. Patients with serious liver functional impairment (AST:100 or above) 6. Patients with moderate to severe heart failure (class 3 or worse based on the New York Heart Association (NYHA)Functional Classification) 7. Patients with urinary tract infection, or genital infection 8. Patients who are pregnant, possibly pregnant, nursing, or planning to conceive a child 9. Patients with a malignant tumor or have a history of malignant tumor (exceptions: those are not on medication for malignant tumor, and have no recurrence of the disease so far and without recurrence risks during this study are allowed to participate) 10. Patients who are prohibited to use tofogliflozin 11. Other patients determined ineligible by an investigator

发起方

Shimane University Faculty of Medicine